Becton Dickinson (BDX) AI Stock Analysis

• Market Cap: $55.73B
• Dividend Yield: 2.13%
• Average Volume (3M): 2.36M
• Price to Earnings (P/E): 33.6
• Beta (1Y): 0.37
• Revenue Growth: 8.23%
• EPS Growth: -2.04%
• Country: US
• Employees: 70,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.96
• Shares Outstanding: 285,418,550
• 10 Day Avg. Volume: 2,260,758
• 30 Day Avg. Volume: 2,361,854
• PEG Ratio: -47.00
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 2.46
• P/FCF Ratio: 20.09
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 3.30
• Enterprise Value/Gross Profit: 7.25
• Enterprise Value/Ebitda: 14.52
• 1Y Price Target: $199.63
• Price Target Upside: 2.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): 14.87
• Revenue Forecast (FY): $22.47B

• Rating: 67 Neutral
• Price Target: $206.00 ▲(5.32% Upside)

Becton Dickinson's overall stock score reflects a stable financial performance with strong revenue growth and profitability margins. The technical analysis suggests a neutral trend, while the valuation indicates a potential overvaluation. The earnings call and corporate events highlight both opportunities and challenges, with strategic initiatives aimed at overcoming macroeconomic headwinds. The company's ability to navigate these challenges will be crucial for future performance.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Operational Efficiency

Improved operational efficiency and margin expansion reflect strong management practices, supporting sustainable profitability.

Strategic Initiatives

Strategic initiatives to cut costs and focus on high-growth areas can drive future growth and enhance competitive positioning.

Negative Factors

Declining Vaccine Demand

Reduced vaccine demand may lead to lower revenue in a significant business segment, impacting overall growth prospects.

Challenges in China

Regulatory challenges in China could hinder growth in a key market, affecting revenue and market expansion opportunities.

Alaris Headwinds

Headwinds from Alaris capital installations may dampen growth, requiring strategic adjustments to mitigate impact.

Becton Dickinson Business Overview & Revenue Model

Company Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

How the Company Makes Money

BDX generates revenue through the sale of its diverse product offerings across its three main segments. The BD Medical segment, which provides medical devices and supplies, contributes significantly to the company's revenue through sales to hospitals and healthcare facilities. BD Life Sciences generates income from its diagnostic systems and reagents, catering to laboratories and healthcare providers that require testing solutions. BD Interventional focuses on products used in minimally invasive procedures, contributing to revenue through partnerships with hospitals and surgical centers. Additionally, BDX capitalizes on long-term contracts and collaborations with healthcare institutions, ensuring a steady revenue stream. The company also invests in research and development to innovate and expand its product lines, which can enhance its market position and drive future earnings.

Becton Dickinson Financial Statement Overview

Summary

Becton Dickinson demonstrates robust financial performance with consistent revenue growth and solid profitability margins. The company has improved its leverage position, although return on equity has seen a slight decline. Cash flow generation remains strong, but there is room for improvement in cash flow conversion. Overall, the company is in a stable financial position with positive growth prospects.

Income Statement

Becton Dickinson shows a solid revenue growth rate of 2.12% in the TTM, with a stable gross profit margin of 45.44%. However, the net profit margin has slightly decreased to 7.68% from 8.45% in the previous year. The EBIT and EBITDA margins remain healthy at 11.42% and 22.70%, respectively, indicating strong operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.34 in the TTM, indicating better leverage management compared to the previous year. Return on equity is at 5.11%, showing a slight decline, which could be a concern for investors. The equity ratio stands at 45.89%, reflecting a stable financial position.

Cash Flow

Free cash flow growth is positive at 4.71% in the TTM, which is a good sign. The operating cash flow to net income ratio is strong at 3.04, suggesting efficient cash generation. However, the free cash flow to net income ratio has slightly decreased to 0.78, indicating a need for improvement in cash flow conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.84B	21.84B	20.18B	19.37B	18.87B	19.13B
Gross Profit	9.92B	9.92B	9.13B	8.17B	8.48B	8.63B
EBITDA	4.96B	4.96B	4.82B	4.40B	4.41B	4.39B
Net Income	1.68B	1.68B	1.71B	1.48B	1.78B	2.09B
Balance Sheet
Total Assets	55.33B	55.33B	57.29B	52.78B	52.93B	53.88B
Cash, Cash Equivalents and Short-Term Investments	859.00M	859.00M	2.16B	1.42B	1.01B	2.29B
Total Debt	19.18B	19.18B	20.11B	15.88B	16.07B	17.61B
Total Liabilities	29.94B	29.94B	31.40B	26.98B	27.65B	30.20B
Stockholders Equity	25.39B	25.39B	25.89B	25.80B	25.28B	23.68B
Cash Flow
Free Cash Flow	2.67B	2.67B	3.07B	2.12B	1.66B	3.42B
Operating Cash Flow	3.43B	3.43B	3.80B	2.99B	2.63B	4.65B
Investing Cash Flow	-818.00M	-818.00M	-5.51B	-716.00M	-3.23B	-1.88B
Financing Cash Flow	-3.62B	-3.62B	2.09B	-1.96B	-591.00M	-3.31B

Becton Dickinson Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 195.59
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Positive. The current price of 195.59 is above the 20-day moving average (MA) of 193.67, above the 50-day MA of 188.35, and above the 200-day MA of 187.84, indicating a bullish trend. The MACD of 2.51 indicates Negative momentum. The RSI at 53.92 is Neutral, neither overbought nor oversold. The STOCH value of 48.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDX.

Becton Dickinson Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ISRG	78 Outperform	$202.94B	75.77	16.90%	―	22.18%	21.37%
HOLX	76 Outperform	$16.72B	30.18	11.12%	―	1.74%	-25.29%
RMD	76 Outperform	$35.75B	25.07	25.41%	0.93%	9.36%	29.56%
WST	68 Neutral	$19.61B	40.37	16.94%	0.32%	4.90%	-0.26%
BDX	67 Neutral	$55.73B	33.63	6.54%	2.13%	8.23%	-2.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	45 Neutral	$9.75B	-36.36	-4.70%	2.73%	-21.20%	-325.40%

Becton Dickinson Corporate Events

Becton Dickinson Announces CFO Transition Plan

On October 15, 2025, BD announced a CFO transition plan as Chris DelOrefice will depart on December 5, 2025, with Vitor Roque stepping in as interim CFO. The company also reported preliminary unaudited revenue results for the fourth quarter and full year fiscal 2025, showing significant growth across various segments despite challenges in the macro environment. BD continues to focus on strategic goals and investments to drive growth and margin momentum.

Becton Dickinson Secures $2.75 Billion Credit Facility

On September 16, 2025, Becton Dickinson and its subsidiary BD Euro Finance entered into a third amended and restated credit agreement with Citibank and other lenders, providing a $2.75 billion senior unsecured revolving credit facility. This agreement, which can be extended up to $3.25 billion, will support the company’s general corporate purposes and includes specific financial covenants and conditions, potentially impacting the company’s financial strategy and flexibility.